Aeglea BioTherapeutics to Participate in September Investment Conferences
September 02 2020 - 4:05PM
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage
biotechnology company developing a new generation of human enzyme
therapeutics as innovative solutions for rare and other high-burden
diseases, today announced it will participate in three investor
conferences in September 2020, including presenting at the H.C.
Wainwright 22nd Annual Global Investment Conference being held
virtually on September 14-16, 2020.
Conference Presentation Details
Conference: H.C. Wainwright Global Investment
ConferenceDate: September 14, 2020 Time: 11:00 a.m.
EDTPresenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s
president and chief executive officer
Location: http://ir.aegleabio.com/events-and-presentations/upcoming-events
To access the live and archived webcast, visit the Presentations
& Events section of the Company’s website. Please connect to
the website at least 15 minutes prior to the presentation to allow
for any software download that may be necessary. Replays of the
webcast will be available for 30 days thereafter.
Conference Participation Details
Conference: Wells Fargo 15th Annual Healthcare Conference Date:
September 9-10, 2020Participants: Anthony G. Quinn, M.B. Ch.B.,
Ph.D., Aeglea’s president and chief executive officer and Charles
N. York II, M.B.A., Aeglea’s chief financial officer Conference:
Cantor Global Healthcare ConferenceDate: September 15-17,
2020Participants: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s
president and chief executive officer and Charles N. York II,
M.B.A., Aeglea’s chief financial officer
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company
redefining the potential of human enzyme therapeutics to benefit
people with rare and other high burden diseases. Aeglea's lead
product candidate, pegzilarginase, is in a pivotal Phase 3 trial
for the treatment of Arginase 1 Deficiency and has received both
Rare Pediatric Disease and Breakthrough Therapy Designation. The
Company initiated a Phase 1/2 clinical trial of ACN00177 for the
treatment of Homocystinuria in the second quarter of 2020. Aeglea
has an active discovery platform, with the most advanced program
for Cystinuria. For more information, please visit
http://aegleabio.com.
Media Contact:Kelly Boothe, Ph.D.Director,
Corporate CommunicationsAeglea BioTherapeutics 512.399.5458
media@aegleabio.com
Investor Contact:Joey PerroneSenior Director,
Finance & Investor RelationsAeglea
BioTherapeuticsinvestors@aegleabio.com
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeglea BioTherapeutics (NASDAQ:AGLE)
Historical Stock Chart
From Sep 2023 to Sep 2024